Oct 2026· VAWKUM Transactions on Computer Sciences· 0 citations· 22 references
TL;DR
An Enhanced Multi-Branch Attention Network is developed that combines Morgan fingerprints, MACCS keys, and physicochemical descriptors through separate feature-processing branches followed by attention-based fusion and suggests that the proposed multi-representation architecture provides a potentially useful screening aid for late-stage toxicity prediction.
Abstract
Late-stage toxicity can lead to substantial attrition in drug development, motivating computational methods that can prioritize compounds for further safety assessment. Recent work such as Trialblazer has demonstrated the utility of molecular fingerprints and bioactivity-derived features for this task. In this study, we develop an Enhanced Multi-Branch Attention Network that combines Morgan fingerprints, MACCS keys, and physicochemical descriptors through separate feature-processing branches followed by attention-based fusion. The training procedure incorporates focal loss, label smoothing, regularization, weighted sampling, and stratified 10-fold cross-validation. The reported experiments use 1,841 compounds for model development and an independent test set of 339 compounds. The reported ensemble test performance is ROC-AUC = 0.910 and MCC = 0.525, with the remaining performance measures retained exactly as obtained from the experimental implementation. The comparison with Trialblazer is presented as a benchmark comparison, while the lower recall of the proposed model is explicitly discussed as an important trade-off. The results suggest that the proposed multi-representation architecture provides a potentially useful screening aid for late-stage toxicity prediction, while experimental validation and careful interpretation remain necessary.
Drug discovery remains constrained by long development timelines, high capital requirements, and substantial attrition, particularly during clinical development and late-stage safety evaluation. Estimates of research and development (R&D) investment required per approved therapeutic agent vary widely across studies and...
Accurate prediction of terminal half-life (t1/2) is paramount for prioritizing drug candidates during the lead optimization stage, as it minimizes the risk of clinical trial failure while optimizing resource allocation. Drugs characterized by suboptimal t1/2 profileseither excessively short or prolongedpresent sign...
Ryoko Terada, Reiko Watanabe, H. Komura et al.· Molecular Pharmaceutics· 0 citations
A unified and standardized benchmarking framework for GDL-based toxicity prediction is introduced, systematically evaluating more than 20 representative approaches under consistent experimental conditions and across multiple datasets and partitioning strategies, enabling a fair and reproducible comparison of model perf...
Noel Suarez-Barro, M. Lama, J. C. Vidal· 0 citations
Accurate prediction of drug-target affinity (DTA) is a core technical step in high-throughput drug screening and targeted drug discovery, which directly affects the efficiency of candidate compound mining and the control of research and development costs. Traditional experimental methods are difficult to meet the requi...
A framework that fine-tunes a general baseline model trained on publicly available data on small, class-specific datasets to retain the baseline’s generalization ability while gaining class-specific accuracy and produce probabilistic outputs that capture uncertainty in the training data is proposed.
C. Barajas, Laura L. Dunphy, Luke C. Mullany et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.